Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Large-Scale Whole-Genome Sequencing Reveals the Genetic Architecture of Primary Membranoproliferative GN and C3 Glomerulopathy.

Levine AP, Chan MMY, Sadeghi-Alavijeh O, Wong EKS, Cook HT, Ashford S, Carss K, Christian MT, Hall M, Harris CL, McAlinden P, Marchbank KJ, Marks SD, Maxwell H, Megy K, Penkett CJ, Mozere M, Stirrups KE, Tuna S, Wessels J, Whitehorn D; MPGN/DDD/C3 Glomerulopathy Rare Disease Group; NIHR BioResource, Johnson SA, Gale DP.

J Am Soc Nephrol. 2020 Jan 9. pii: ASN.2019040433. doi: 10.1681/ASN.2019040433. [Epub ahead of print]

PMID:
31919107
2.

Hyperfunctional complement C3 promotes C5-dependent atypical hemolytic uremic syndrome in mice.

Smith-Jackson K, Yang Y, Denton H, Pappworth IY, Cooke K, Barlow PN, Atkinson JP, Liszewski MK, Pickering MC, Kavanagh D, Cook HT, Marchbank KJ.

J Clin Invest. 2019 Mar 1;129(3):1061-1075. doi: 10.1172/JCI99296. Epub 2019 Feb 4.

3.

Utilization of Staphylococcal Immune Evasion Protein Sbi as a Novel Vaccine Adjuvant.

Yang Y, Back CR, Gräwert MA, Wahid AA, Denton H, Kildani R, Paulin J, Wörner K, Kaiser W, Svergun DI, Sartbaeva A, Watts AG, Marchbank KJ, van den Elsen JMH.

Front Immunol. 2019 Jan 11;9:3139. doi: 10.3389/fimmu.2018.03139. eCollection 2018.

4.

Targeting properdin in the treatment of atypical haemolytic uraemic syndrome: better than eculizumab?

Smith-Jackson K, Marchbank KJ.

Ann Transl Med. 2018 Nov;6(Suppl 1):S62. doi: 10.21037/atm.2018.10.35. No abstract available.

5.

An Engineered Complement Factor H Construct for Treatment of C3 Glomerulopathy.

Yang Y, Denton H, Davies OR, Smith-Jackson K, Kerr H, Herbert AP, Barlow PN, Pickering MC, Marchbank KJ.

J Am Soc Nephrol. 2018 Jun;29(6):1649-1661. doi: 10.1681/ASN.2017091006. Epub 2018 Mar 27.

6.

Modulation of the Alternative Pathway of Complement by Murine Factor H-Related Proteins.

Antonioli AH, White J, Crawford F, Renner B, Marchbank KJ, Hannan JP, Thurman JM, Marrack P, Holers VM.

J Immunol. 2018 Jan 1;200(1):316-326. doi: 10.4049/jimmunol.1602017. Epub 2017 Nov 29.

7.

A novel C3d-containing oligomeric vaccine provides insight into the viability of testing human C3d-based vaccines in mice.

He YG, Pappworth IY, Rossbach A, Paulin J, Mavimba T, Hayes C, Kulik L, Holers VM, Knight AM, Marchbank KJ.

Immunobiology. 2018 Jan;223(1):125-134. doi: 10.1016/j.imbio.2017.10.002. Epub 2017 Oct 4.

8.

Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland.

Brocklebank V, Johnson S, Sheerin TP, Marks SD, Gilbert RD, Tyerman K, Kinoshita M, Awan A, Kaur A, Webb N, Hegde S, Finlay E, Fitzpatrick M, Walsh PR, Wong EKS, Booth C, Kerecuk L, Salama AD, Almond M, Inward C, Goodship TH, Sheerin NS, Marchbank KJ, Kavanagh D.

Kidney Int. 2017 Nov;92(5):1261-1271. doi: 10.1016/j.kint.2017.04.028. Epub 2017 Jul 24.

9.

Thermal stability, storage and release of proteins with tailored fit in silica.

Chen YC, Smith T, Hicks RH, Doekhie A, Koumanov F, Wells SA, Edler KJ, van den Elsen J, Holman GD, Marchbank KJ, Sartbaeva A.

Sci Rep. 2017 Apr 24;7:46568. doi: 10.1038/srep46568.

10.

Thrombotic Microangiopathy in Inverted Formin 2-Mediated Renal Disease.

Challis RC, Ring T, Xu Y, Wong EK, Flossmann O, Roberts IS, Ahmed S, Wetherall M, Salkus G, Brocklebank V, Fester J, Strain L, Wilson V, Wood KM, Marchbank KJ, Santibanez-Koref M, Goodship TH, Kavanagh D.

J Am Soc Nephrol. 2017 Apr;28(4):1084-1091. doi: 10.1681/ASN.2015101189. Epub 2016 Dec 14.

11.

Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients.

Schmidt CQ, Harder MJ, Nichols EM, Hebecker M, Anliker M, Höchsmann B, Simmet T, Csincsi ÁI, Uzonyi B, Pappworth IY, Ricklin D, Lambris JD, Schrezenmeier H, Józsi M, Marchbank KJ.

Immunobiology. 2016 Apr;221(4):503-11. doi: 10.1016/j.imbio.2015.12.009. Epub 2016 Jan 6.

12.

The role of ADAMTS-13 activity and complement mutational analysis in differentiating acute thrombotic microangiopathies.

Phillips EH, Westwood JP, Brocklebank V, Wong EK, Tellez JO, Marchbank KJ, McGuckin S, Gale DP, Connolly J, Goodship TH, Kavanagh D, Scully MA.

J Thromb Haemost. 2016 Jan;14(1):175-85. doi: 10.1111/jth.13189. Epub 2016 Jan 11.

13.

A De Novo Deletion in the Regulators of Complement Activation Cluster Producing a Hybrid Complement Factor H/Complement Factor H-Related 3 Gene in Atypical Hemolytic Uremic Syndrome.

Challis RC, Araujo GS, Wong EK, Anderson HE, Awan A, Dorman AM, Waldron M, Wilson V, Brocklebank V, Strain L, Morgan BP, Harris CL, Marchbank KJ, Goodship TH, Kavanagh D.

J Am Soc Nephrol. 2016 Jun;27(6):1617-24. doi: 10.1681/ASN.2015010100. Epub 2015 Oct 21.

14.

A CD21 low phenotype, with no evidence of autoantibodies to complement proteins, is consistent with a poor prognosis in CLL.

Nichols EM, Jones R, Watson R, Pepper CJ, Fegan C, Marchbank KJ.

Oncotarget. 2015 Oct 20;6(32):32669-80. doi: 10.18632/oncotarget.5404.

15.

An extended mini-complement factor H molecule ameliorates experimental C3 glomerulopathy.

Nichols EM, Barbour TD, Pappworth IY, Wong EK, Palmer JM, Sheerin NS, Pickering MC, Marchbank KJ.

Kidney Int. 2015 Dec;88(6):1314-1322. doi: 10.1038/ki.2015.233. Epub 2015 Jul 29.

16.

Autoantibodies to CD59, CD55, CD46 or CD35 are not associated with atypical haemolytic uraemic syndrome (aHUS).

Watson R, Wearmouth E, McLoughlin AC, Jackson A, Ward S, Bertram P, Bennaceur K, Barker CE, Pappworth IY, Kavanagh D, Lea SM, Atkinson JP, Goodship TH, Marchbank KJ.

Mol Immunol. 2015 Feb;63(2):287-96. doi: 10.1016/j.molimm.2014.07.017. Epub 2014 Aug 21.

17.

A novel method for direct measurement of complement convertases activity in human serum.

Blom AM, Volokhina EB, Fransson V, Strömberg P, Berghard L, Viktorelius M, Mollnes TE, López-Trascasa M, van den Heuvel LP, Goodship TH, Marchbank KJ, Okroj M.

Clin Exp Immunol. 2014 Oct;178(1):142-53. doi: 10.1111/cei.12388.

18.

Characterization of a factor H mutation that perturbs the alternative pathway of complement in a family with membranoproliferative GN.

Wong EK, Anderson HE, Herbert AP, Challis RC, Brown P, Reis GS, Tellez JO, Strain L, Fluck N, Humphrey A, Macleod A, Richards A, Ahlert D, Santibanez-Koref M, Barlow PN, Marchbank KJ, Harris CL, Goodship TH, Kavanagh D.

J Am Soc Nephrol. 2014 Nov;25(11):2425-33. doi: 10.1681/ASN.2013070732. Epub 2014 Apr 10.

19.

Standardisation of the factor H autoantibody assay.

Watson R, Lindner S, Bordereau P, Hunze EM, Tak F, Ngo S, Zipfel PF, Skerka C, Dragon-Durey MA, Marchbank KJ.

Immunobiology. 2014 Jan;219(1):9-16. doi: 10.1016/j.imbio.2013.06.004. Epub 2013 Jun 26.

PMID:
23891327
20.

Factor H autoantibodies in membranoproliferative glomerulonephritis.

Goodship TH, Pappworth IY, Toth T, Denton M, Houlberg K, McCormick F, Warland D, Moore I, Hunze EM, Staniforth SJ, Hayes C, Cavalcante DP, Kavanagh D, Strain L, Herbert AP, Schmidt CQ, Barlow PN, Harris CL, Marchbank KJ.

Mol Immunol. 2012 Oct;52(3-4):200-6. doi: 10.1016/j.molimm.2012.05.009. Epub 2012 Jun 20.

PMID:
22721707
21.

Postpartum aHUS secondary to a genetic abnormality in factor H acquired through liver transplantation.

Brown JH, Tellez J, Wilson V, Mackie IJ, Scully M, Tredger MM, Moore I, McDougall NI, Strain L, Marchbank KJ, Sheerin NS, O'Grady J, Harris CL, Goodship TH.

Am J Transplant. 2012 Jun;12(6):1632-6. doi: 10.1111/j.1600-6143.2012.03991.x. Epub 2012 Mar 15.

22.

Factor I autoantibodies in patients with atypical hemolytic uremic syndrome: disease-associated or an epiphenomenon?

Kavanagh D, Pappworth IY, Anderson H, Hayes CM, Moore I, Hunze EM, Bennaceur K, Roversi P, Lea S, Strain L, Ward R, Plant N, Nailescu C, Goodship TH, Marchbank KJ.

Clin J Am Soc Nephrol. 2012 Mar;7(3):417-26. doi: 10.2215/CJN.05750611. Epub 2012 Jan 5.

23.

A novel hybrid CFH/CFHR3 gene generated by a microhomology-mediated deletion in familial atypical hemolytic uremic syndrome.

Francis NJ, McNicholas B, Awan A, Waldron M, Reddan D, Sadlier D, Kavanagh D, Strain L, Marchbank KJ, Harris CL, Goodship TH.

Blood. 2012 Jan 12;119(2):591-601. doi: 10.1182/blood-2011-03-339903. Epub 2011 Nov 4.

PMID:
22058112
24.

Mice expressing human CR1/CD35 have an enhanced humoral immune response to T-dependent antigens but fail to correct the effect of premature human CR2 expression.

Pappworth IY, Hayes C, Dimmick J, Morgan BP, Holers VM, Marchbank KJ.

Immunobiology. 2012 Feb;217(2):147-57. doi: 10.1016/j.imbio.2011.06.001. Epub 2011 Jun 25.

25.

Complement factor h autoantibodies and age-related macular degeneration.

Dhillon B, Wright AF, Tufail A, Pappworth I, Hayward C, Moore I, Strain L, Kavanagh D, Barlow PN, Herbert AP, Schmidt CQ, Armbrecht AM, Laude A, Deary IJ, Staniforth SJ, Holmes LV, Goodship TH, Marchbank KJ.

Invest Ophthalmol Vis Sci. 2010 Nov;51(11):5858-63. doi: 10.1167/iovs.09-5124. Epub 2010 Jun 30.

PMID:
20592223
26.

Triggering of atypical hemolytic uremic syndrome by influenza A (H1N1).

Bento D, Mapril J, Rocha C, Marchbank KJ, Kavanagh D, Barge D, Strain L, Goodship TH, Meneses-Oliveira C.

Ren Fail. 2010 Jul;32(6):753-6. doi: 10.3109/0886022X.2010.486491.

PMID:
20540647
27.

Impact of compound heterozygous complement factor H mutations on development of atypical hemolytic uremic syndrome-A pedigree revisited.

Johnson SA, Williams JM, Hakobyan S, Richards A, Perkins SJ, Marchbank KJ, Goodship TH, Morgan BP, Taylor CM, Savage CO.

Mol Immunol. 2010 Apr;47(7-8):1585-91. doi: 10.1016/j.molimm.2009.12.001. Epub 2010 Mar 20.

PMID:
20304497
28.

Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome.

Moore I, Strain L, Pappworth I, Kavanagh D, Barlow PN, Herbert AP, Schmidt CQ, Staniforth SJ, Holmes LV, Ward R, Morgan L, Goodship TH, Marchbank KJ.

Blood. 2010 Jan 14;115(2):379-87. doi: 10.1182/blood-2009-05-221549. Epub 2009 Oct 27.

29.

Defective B cell ontogeny and humoral immune response in mice prematurely expressing human complement receptor 2 (CR2, CD21) is similar to that seen in aging wild type mice.

Twohig JP, Pappworth IY, Sivasankar B, Kulik L, Bull M, Holers VM, Wang EC, Marchbank KJ.

Mol Immunol. 2009 Jun;46(10):2002-13. doi: 10.1016/j.molimm.2009.03.007. Epub 2009 Apr 8.

30.

Increased B cell deletion and significantly reduced auto-antibody titre due to premature expression of human complement receptor 2 (CR2, CD21).

Pappworth IY, Kulik L, Haluszczak C, Reuter JW, Holers VM, Marchbank KJ.

Mol Immunol. 2009 Mar;46(6):1042-9. doi: 10.1016/j.molimm.2008.08.273. Epub 2009 Feb 1.

31.

Defective B cell ontogeny and immune response in human complement receptor 2 (CR2, CD21) transgenic mice is partially recovered in the absence of C3.

Twohig J, Kulik L, Haluszczak C, Reuter J, Rossbach A, Bull M, Holers VM, Marchbank KJ.

Mol Immunol. 2007 Jul;44(13):3434-44. Epub 2007 Mar 26.

32.

Intrinsic B cell hypo-responsiveness in mice prematurely expressing human CR2/CD21 during B cell development.

Kulik L, Marchbank KJ, Lyubchenko T, Kuhn KA, Liubchenko GA, Haluszczak C, Gipson MG, Boackle SA, Holers VM.

Eur J Immunol. 2007 Mar;37(3):623-33. Erratum in: Eur J Immunol. 2007 Apr;37(4):1149. Gibson, Matthew G [corrected to Gipson, Matthew G].

33.

CD59a deficient mice display reduced B cell activity and antibody production in response to T-dependent antigens.

Sivasankar B, Donev RM, Longhi MP, Hughes TR, Davies R, Cole DS, Morgan BP, Marchbank KJ.

Mol Immunol. 2007 Apr;44(11):2978-87. Epub 2007 Feb 12.

PMID:
17296227
34.

B cells from mice prematurely expressing human complement receptor type 2 are unresponsive to T-dependent antigens.

Birrell L, Kulik L, Morgan BP, Holers VM, Marchbank KJ.

J Immunol. 2005 Jun 1;174(11):6974-82.

35.

Complement: central to innate immunity and bridging to adaptive responses.

Morgan BP, Marchbank KJ, Longhi MP, Harris CL, Gallimore AM.

Immunol Lett. 2005 Mar 15;97(2):171-9. Epub 2004 Dec 7. Review.

PMID:
15752555
36.

Characterization of the mouse analogues of CD59 using novel monoclonal antibodies: tissue distribution and functional comparison.

Harris CL, Hanna SM, Mizuno M, Holt DS, Marchbank KJ, Morgan BP.

Immunology. 2003 May;109(1):117-26.

37.
38.

Loxosceles spider venom induces metalloproteinase mediated cleavage of MCP/CD46 and MHCI and induces protection against C-mediated lysis.

Van Den Berg CW, De Andrade RM, Magnoli FC, Marchbank KJ, Tambourgi DV.

Immunology. 2002 Sep;107(1):102-10.

39.

Expression of human complement receptor 2 (CR2, CD21) in Cr2-/- mice restores humoral immune function.

Marchbank KJ, Watson CC, Ritsema DF, Holers VM.

J Immunol. 2000 Sep 1;165(5):2354-61.

40.

Mechanisms of complement resistance induced by non-lethal complement attack and by growth arrest.

Marchbank KJ, van den Berg CW, Morgan BP.

Immunology. 1997 Apr;90(4):647-53.

41.

Molecular cloning, chromosomal localization, expression, and functional characterization of the mouse analogue of human CD59.

Powell MB, Marchbank KJ, Rushmere NK, van den Berg CW, Morgan BP.

J Immunol. 1997 Feb 15;158(4):1692-702.

PMID:
9029105

Supplemental Content

Loading ...
Support Center